Please select the eligibility criteria that correspond to the clinical trial below.
Title: The Women In Steady Exercise Research (WISER) Survivor Trial & Cost of Illness and Cost Effectiveness of Alternative Management Strategies
Brief Summary: WISER Survivor is a one year weight loss and exercise study for sedentary breast cancer survivors who are overweight or obese with breast cancer related lymphedema. There will be four groups in this trial: exercise only, weight loss only, exercise and weight-loss combined, and a control group. The primary purpose of this study is to test the effects of these interventions on clinical lymphedema outcomes. Secondary outcomes include weight loss, breast cancer related biomarkers, and quality of life. To the extent that funding will be available, participants will be followed long term to examine effects on recurrence and mortality.


Options:
A: Inclusion Criteria:

* breast cancer survivor
* overweight or obese (BMI of 25 or greater)
* must have breast cancer related lymphedema
* at least 6 months post-treatment (e.g. surgery, chemotherapy, or radiotherapy) but there will be no upper limit on time elapsed from diagnosis
* the eligible age range will have no lower limit.
* currently free of cancer

Exclusion Criteria:

* medical conditions or medications that would prohibit participation in an exercise program or would negatively impact our ability to test our primary aims
* inability to walk for 6 minutes unaided
* extremely obese (body mass index greater or equal to 50 kg/m2)
* plans for additional (e.g. curative or reconstructive) surgery during the study period
* self-report of weight-lifting within the past year
* already engaging in 3 or more times weekly aerobic activity of moderate intensity
* planning to move away from the area over the next year
* current use of weight loss medication (OTC or prescription)
* self-report of alcohol or substance abuse within the past 12 months, including at-risk drinking (current consumption of more than 14 alcoholic drinks per week)
* weight loss of greater than 10 % in the past 3 months
* history of bariatric surgery
* women who are pregnant
B: DISEASE CHARACTERISTICS:

* Stage 0-IIIA breast cancer survivor
* Completed cancer treatment within the past 36 months (except for tamoxifen/aromatase inhibitors)

  * At least 2 months since prior surgery, adjuvant therapy, or radiotherapy, whichever occurred last
* Women who are not currently practicing yoga and have not participated in any of the following activities:

  * Meditation, tai chi, or related activities
  * Yoga or tai chi within the past 6 months
  * Had classes for or practiced yoga for more than 3 months
* Women who typically engage in a total of 5 or more hours of vigorous physical activity per week are not eligible
* No inflammatory breast cancer

PATIENT CHARACTERISTICS:

Inclusion criteria:

* Hemoglobin ≥ 10 g/dL (patients with a hemoglobin of \< 10 g/dL may be retested in 6 weeks after treatment of anemia and allowed to participate in study if blood counts recovered)
* Physically able to fully participate in yoga intervention

Exclusion criteria:

* Inability to comfortably get up and down from the floor 2-3 times in a session
* Breathing problems requiring use of oxygen
* Problems walking without a cane or walker assistance
* Prior knee or hip replacement with limited movement in the joint
* Inability to comfortably lie on the stomach
* Alcohol, or drug abuse
* Diagnosis of any of the following conditions:

  * Diabetes
  * Chronic obstructive pulmonary disease
  * Uncontrolled hypertension
  * Evidence of liver or kidney failure
  * Symptomatic ischemic heart disease
  * Significant visual or auditory problems
  * Mental disorder or cognitive impairment
  * Notable serious cardiovascular history (e.g., prior life-threatening abnormal heart rhythms)
  * Other medical conditions involving the immune system such as autoimmune and/or inflammatory diseases including rheumatoid arthritis and ulcerative colitis
* History of breast or any other cancer, except basal or squamous cell skin cancer

PRIOR CONCURRENT THERAPY:

* See Disease Characteristics
* No regular use of medications with major immunological consequences (e.g., steroids)
C: Inclusion Criteria:

* Postmenopausal women aged 18 years or older; Postmenopause is defined as Natural menopause with menses \>1 year ago or Serum FSH (\> 20 IU/ l), and E2 levels in the postmenopausal range or patients who had bilateral oophorectomy
* Histologically / cytologically confirmed primary diagnosis of early breast cancer (M0) with hormone sensitive tumour (ER+ve and/or PgR+ve)
* Patients, who underwent breast cancer surgery and, if appl. radiation therapy and/or neo/adjuvant chemotherapy and have taken adjuvant endocrine treatment with anastrozole (upfront or following two to three years of tamoxifen) min 3 max 6 months
* In case of a previous therapy with tamoxifen (switch-therapy), duration of tamoxifen treatment for at least two and up to three years.

Exclusion Criteria:

* Patients with severe renal function disorders (Creatinine clearance \< 20 ml/min or Patients with moderate or severe disorders of hepatic function
* Concomitant treatment with drugs known to affect sex hormonal status and tamoxifen
* Patients with ductal carcinoma in situ (DCIS) without primary diagnosis of early breast cancer (M0)
* Evidence of any significant clinical disorder or laboratory finding which in the opinion of the investigator, makes it undesirable for the patient to participate in the program
D: Inclusion Criteria:

* Female
* Cancer diagnosis
* Postmenopausal

Exclusion Criteria:

* Health condition contraindication to moderate physical activity

Answer: A